Cepheid Q4 Revenues Up 12 Percent | GenomeWeb

This article has been updated with comments from Cepheid's CEO, John Bishop.

NEW YORK (GenomeWeb) – Cepheid reported after the close of the market on Tuesday that its fourth-quarter revenues rose 12 percent year-over-year, and attributed the growth to what it called record reagent revenues and GeneXpert system placements.

The Sunnyvale, Calif.-based firm reported revenues of $147.0 million for the three months ended Dec. 31, 2015, up from $131.5 million in Q4 2014 and in line with the consensus analyst estimate of $146.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.